Francesco Boccalatte
Principal Investigator
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (3)
While the mutational landscape across early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) and ETP-like leukemia is known, establishing a unified framework that activates stem cell genes characteristic of these tumors remains elusive. Using complementary mouse and human models, chromatin mapping, and enhancer profiling, we show that the coactivator ZMIZ1 promotes normal and malignant ETP population growth by inducing the transcription factor MYB in feedforward circuits to convergently activate oncogenes (MEF2C, MYCN, and BCL2) through essential enhancers. A key superenhancer, the N-Myc regulating enhancer (NMRE), drives malignant ETP population growth but is dispensable for normal lymphopoiesis. This network of stem cell superenhancers identifies treatment-resistant tumors and poor survival outcomes; unifies diverse ETP-ALLs; and contributes to cardinal features of the recently genomically identified high-risk bone marrow progenitor-like (BMP-like) ETP-ALL tumor—stem cell/myeloid gene expression, inhibited NOTCH1-induced T-cell development, aggressive clinical behavior, and venetoclax sensitivity. Since ZMIZ1 is dispensable for essential homeostasis, it might be possible to safely target this network to treat high-risk diseases.
Year:
2025
T-cell acute lymphoblastic leukemia is a biologically heterogeneous malignancy characterized by diverse transcriptional and genomic alterations. Recent studies have defined a set of recurrent molecular subtypes associated with distinct differentiation stages and clinical outcomes. However, no unified framework currently exists for assigning these subtypes in a standardized and accessible manner. Existing approaches often rely on mutation or fusion detection and may overlook broader transcriptional programs. The lack of a comprehensive, transcriptome-based classification tool has hampered the use of subtype-specific insights in both research and clinical settings. Here, we present a machine learning–based classifier trained on transcriptomic data to predict previously defined multi-omic subtypes of T-cell acute lymphoblastic leukemia. The model accurately assigns subtype identity across patient samples and cell lines, and provides a practical tool for standardized molecular stratification, supporting future integration into diagnostic and translational workflows, as demonstrated by its ability to reveal subtype-specific patterns of relapse.
Year:
2025
Year:
2023
Collaborators (4)
Aristotelis Tsirigos
Associate Professor (Research) of Pathology
NYU School of Medicine
Russell J.H. Ryan
Associate Professor
University of Michigan Medical School
Jimin Tan
Assistant Professor
NYU School of Medicine
Kai Tan
Professor
University of Pennsylvania
Make your next move.
Prepare your application
Review drafts before you send them.